Ascendis Pharma legal chief plans $4.44M share sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Ascendis Pharma A/S Executive VP and Chief Legal Officer Michael Wolff Jensen reported plans to sell 18,349 ordinary shares, with an aggregate market value of $4,442,109 based on an indicative market price of $242.09 per share. The notice lists an approximate sale date of March 2, 2026.
The sales are described as non-discretionary transactions over multiple days under an established Rule 10b5-1 plan adopted September 7, 2023, in connection with vesting and settlement of equity awards. Jensen also reported selling 10,000 ordinary shares on December 4, 2025, for gross proceeds of $2,081,018.69.
Key Figures
Key Terms
10B51 plan regulatory
restricted stock vesting financial
gross proceeds financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.